Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1982 1
1983 1
1985 2
1986 1
1987 1
1988 2
1990 1
1991 1
1992 2
1993 2
1994 3
1995 3
1996 2
1997 4
1998 1
1999 3
2000 5
2001 9
2002 4
2003 9
2004 12
2005 14
2006 13
2007 12
2008 7
2009 5
2010 11
2011 7
2012 2
2013 2
2014 12
2015 8
2016 8
2017 5
2018 10
2019 12
2020 11
2021 3
2022 5
2023 2
2024 3
2025 3
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

206 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
ADVANCE Collaborative Group; Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. ADVANCE Collaborative Group, et al. N Engl J Med. 2008 Jun 12;358(24):2560-72. doi: 10.1056/NEJMoa0802987. Epub 2008 Jun 6. N Engl J Med. 2008. PMID: 18539916 Free article. Clinical Trial.
METHODS: We randomly assigned 11,140 patients with type 2 diabetes to undergo either standard glucose control or intensive glucose control, defined as the use of gliclazide (modified release) plus other drugs as required to achieve a glycated hemoglobin value of 6.5% or le …
METHODS: We randomly assigned 11,140 patients with type 2 diabetes to undergo either standard glucose control or intensive glucose control, …
Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials.
Landman GW, de Bock GH, van Hateren KJ, van Dijk PR, Groenier KH, Gans RO, Houweling ST, Bilo HJ, Kleefstra N. Landman GW, et al. PLoS One. 2014 Feb 12;9(2):e82880. doi: 10.1371/journal.pone.0082880. eCollection 2014. PLoS One. 2014. PMID: 24533045 Free PMC article.
OBJECTIVE AND DESIGN: Gliclazide has been associated with a low risk of hypoglycemic episodes and beneficial long-term cardiovascular safety in observational cohorts. ...Compared to other glucose lowering agents except metformin, gliclazide was slightly more effecti …
OBJECTIVE AND DESIGN: Gliclazide has been associated with a low risk of hypoglycemic episodes and beneficial long-term cardiovascular …
Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis.
Domecq JP, Prutsky G, Leppin A, Sonbol MB, Altayar O, Undavalli C, Wang Z, Elraiyah T, Brito JP, Mauck KF, Lababidi MH, Prokop LJ, Asi N, Wei J, Fidahussein S, Montori VM, Murad MH. Domecq JP, et al. J Clin Endocrinol Metab. 2015 Feb;100(2):363-70. doi: 10.1210/jc.2014-3421. Epub 2015 Jan 15. J Clin Endocrinol Metab. 2015. PMID: 25590213 Free PMC article.
Weight gain was associated with the use of amitriptyline (1.8 kg), mirtazapine (1.5 kg), olanzapine (2.4 kg), quetiapine (1.1 kg), risperidone (0.8 kg), gabapentin (2.2 kg), tolbutamide (2.8 kg), pioglitazone (2.6 kg), glimepiride (2.1 kg), gliclazide (1.8 kg), glyburide ( …
Weight gain was associated with the use of amitriptyline (1.8 kg), mirtazapine (1.5 kg), olanzapine (2.4 kg), quetiapine (1.1 kg), risperido …
Fasting and postprandial kidney haemodynamic effects of empagliflozin and linagliptin in mono- and combination therapy compared to gliclazide in overweight people with type 2 diabetes (RACELINES): A randomised, double-blind trial.
van Baar MJB, Muskiet MHA, Scholtes RA, Touw DJ, Nieuwdorp M, Kramer MHH, Joles JA, Cherney DZI, Bjornstad P, Krebber MM, van Raalte DH. van Baar MJB, et al. Diabetes Obes Metab. 2025 Jul;27(7):3943-3956. doi: 10.1111/dom.16431. Epub 2025 May 6. Diabetes Obes Metab. 2025. PMID: 40326063 Free PMC article. Clinical Trial.
AIMS: We aimed to assess the effects of empagliflozin and linagliptin in mono- and combination therapy compared to the initiation and intensification of SU-derivative gliclazide treatment on fasting and postprandial kidney haemodynamic function. MATERIALS AND METHODS: We c …
AIMS: We aimed to assess the effects of empagliflozin and linagliptin in mono- and combination therapy compared to the initiation and intens …
Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis.
Zhang YS, Zheng YD, Yuan Y, Chen SC, Xie BC. Zhang YS, et al. Front Endocrinol (Lausanne). 2021 Oct 14;12:735824. doi: 10.3389/fendo.2021.735824. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34721294 Free PMC article.
Some drugs (omarigliptin, sitagliptin, vildagliptin, saxagliptin, empagliflozin, ertugliflozin, rosiglitazone, pioglitazone, and nateglinide) may increase the risk of fracture, while others (such as dulaglutide, exenatide, liraglutide, semaglutide, lixisenatide, linagliptin, alog …
Some drugs (omarigliptin, sitagliptin, vildagliptin, saxagliptin, empagliflozin, ertugliflozin, rosiglitazone, pioglitazone, and nateglinide …
Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents.
Chan SP, Colagiuri S. Chan SP, et al. Diabetes Res Clin Pract. 2015 Oct;110(1):75-81. doi: 10.1016/j.diabres.2015.07.002. Epub 2015 Jul 9. Diabetes Res Clin Pract. 2015. PMID: 26361859
METHODS: Two reviewers searched MEDLINE for studies of 12 weeks duration in adults with type 2 diabetes. The key search word was "gliclazide", filtered with "randomized controlled trial", "human" and "19+ years". Differences were explored in mean change in glycated hemogl …
METHODS: Two reviewers searched MEDLINE for studies of 12 weeks duration in adults with type 2 diabetes. The key search word was "glicla …
Double-blind, randomized, multicentre study of the efficacy and safety of gliclazide-modified release in the treatment of Chinese type 2 diabetic patients.
Lu CH, Chang CC, Chuang LM, Wang CY, Jiang YD, Wu HP. Lu CH, et al. Diabetes Obes Metab. 2006 Mar;8(2):184-91. doi: 10.1111/j.1463-1326.2005.00501.x. Diabetes Obes Metab. 2006. PMID: 16448522 Clinical Trial.
BACKGROUND AND AIM: Gliclazide-modified release (gliclazide MR) is a new formulation of the sulfonylurea gliclazide designed for once-daily administration. ...The safety profiles of gliclazide MR and gliclazide were similar with a small number o …
BACKGROUND AND AIM: Gliclazide-modified release (gliclazide MR) is a new formulation of the sulfonylurea gliclazide des …
Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation.
Johnston R, Uthman O, Cummins E, Clar C, Royle P, Colquitt J, Tan BK, Clegg A, Shantikumar S, Court R, O'Hare JP, McGrane D, Holt T, Waugh N. Johnston R, et al. Health Technol Assess. 2017 Jan;21(2):1-218. doi: 10.3310/hta21020. Health Technol Assess. 2017. PMID: 28105986 Free PMC article.
In monotherapy, the three drugs do not appear cost-effective compared with gliclazide or pioglitazone, but may be competitive against sitagliptin (Januvia, Boehringer Ingelheim, Bracknell, UK). ...
In monotherapy, the three drugs do not appear cost-effective compared with gliclazide or pioglitazone, but may be competitive against …
Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide.
Belcher G, Lambert C, Goh KL, Edwards G, Valbuena M. Belcher G, et al. Int J Clin Pract. 2004 Sep;58(9):833-7. doi: 10.1111/j.1742-1241.2004.00291.x. Int J Clin Pract. 2004. PMID: 15529516
Major cardiovascular outcomes during four one-year, double-blind trials in over 3700 patients with type 2 diabetes randomised to either a thiazolidinedione, pioglitazone, metformin or a sulphonylurea, gliclazide treatment have been combined. Mean blood pressure was slightl …
Major cardiovascular outcomes during four one-year, double-blind trials in over 3700 patients with type 2 diabetes randomised to either a th …
Modified-release gliclazide acutely improves recovery but causes undesirable blood glucose decrease after a resistance exercise session in healthy adults: a pilot study for a randomized clinical trial.
Martins JB, Zanella D, Nunes RB, Collado PS, Lehnen AM. Martins JB, et al. Arch Endocrinol Metab. 2024 Jul 30;68:e230381. doi: 10.20945/2359-4292-2023-0381. eCollection 2024. Arch Endocrinol Metab. 2024. PMID: 39420894 Free PMC article. Clinical Trial.
Blood glucose was measured with a glucometer before, during, and after the exercise sessions. RESULTS: Gliclazide did not enhance volume load for bench press (placebo: 2,698.0 923.0 kg; gliclazide: 2,675.0 1,088.0 kg; p = 0.073) or leg press (placebo: 10,866.0 …
Blood glucose was measured with a glucometer before, during, and after the exercise sessions. RESULTS: Gliclazide did not enhance vol …
206 results